Apr 30 |
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
|
Apr 8 |
Biora Therapeutics files to sell 10.7M common shares for holders
|
Apr 8 |
Biora Therapeutics wins new patent covering Biojet liquid jet delivery technology
|
Apr 8 |
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
|
Apr 4 |
Biora Therapeutics reports positive results from its clinical trial of BT-600
|
Apr 4 |
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
|
Apr 3 |
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
Apr 1 |
Biora Therapeutics Full Year 2023 Earnings: Beats Expectations
|
Apr 1 |
Biora Therapeutics announces $6M registered direct offering and concurrent private placement
|
Apr 1 |
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|